The Latest Cardiac and Vascular News
PARIS–(BUSINESS WIRE)–Partnership between the University of Birmingham and Acticor Biotech (Paris:ALACT) will see patients with heart attacks treated with glenzocimab, a promising new class of drug for the first time. A potential new drug to improve the long-term outcomes for heart attack patients will be trialled in the UK. With the signing […]
Significant clinical progress in the treatment of stroke with glenzocimab: Positive results from the ACTIMIS phase 1b/2a study Patent granted to protect glenzocimab in thrombotic diseases in Europe until 2036 Obtained “PRIME” status from the European Medicines Agency More than 150 patients enrolled to date in the ACTISAVE Phase 2/3 […]
Issuance of convertible bonds into shares for an amount of €3.9 M to historical shareholders Issuance of simple bonds with attached warrants to a new French investor for €2.0 M PARIS–(BUSINESS WIRE)–Regulatory News: Acticor Biotech (Euronext Growth Paris – ISIN : FR0014005OJ5 – ALACT), a clinical-stage biotechnology company developing an […]
PARIS–(BUSINESS WIRE)–ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT) (Paris:ALACT), a clinical-stage biotechnology company developing innovative drugs for the treatment of cardiovascular emergencies, particularly stroke, today announced the enrollment of the first patient in the USA in its Phase 2/3 registration study ACTISAVE, which is evaluating glenzocimab in patients with acute ischemic […]
Strengthening discussions with regulatory authorities to accelerate the clinical development of glenzocimab for its potential benefit in the treatment of stroke 87 patients already enrolled in Europe in the ACTISAVE Phase 2/3 registration study in stroke patients ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical-stage biotechnology company developing innovative drugs […]
PARIS–(BUSINESS WIRE)–Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies, today discloses the total number of voting rights and shares as of June 30, 2022 (pursuant to Article L. 233-8 II of the French Commercial […]
This patent protects the use of glenzocimab in thrombotic diseases until 2036 This patent has already been granted in the United States and Singapore and is in the process of being granted in other countries such as Japan PARIS–(BUSINESS WIRE)–Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical-stage biotechnology […]
PARIS–(BUSINESS WIRE)–Regulatory News: ACTICOR BIOTECH (ISIN : FR0014005OJ5 – ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies, today discloses the total number of voting rights and shares as of April 30, 2022 (pursuant to Article L. 233-8 II of the French […]
Notifications
